Skip to content
Research/Peptides/Pentadecapeptide (BPC-157)

Pentadecapeptide (BPC-157)

Body Protection Compound-157. 15-amino acid synthetic peptide with remarkable tissue repair, gut healing, and anti-inflammatory effects. Derived from human gastric juice.

Intelligence Profile

Science

Mechanism of Action

The molecular and physiological mechanisms of BPC-157 are still being elucidated, with research suggesting multiple pathways of action rather than a single target mechanism.

Vascular Effects

Recent evidence demonstrates that BPC-157 induces endothelium-dependent vasorelaxation through nitric oxide (NO) pathways. In human internal mammary artery studies, BPC-157 appears to promote vasodilation via NO-mediated mechanisms, which may contribute to its protective effects in ischemia-reperfusion injury models.

Cytoprotective Properties

Research suggests BPC-157 functions as a cytoprotective agent with effects spanning multiple organ systems. Studies in rat models indicate the peptide may help maintain cellular integrity during various forms of physiological stress, including electrolyte disturbances and tissue injury, though the precise molecular targets remain unclear.

Acetylcholinesterase Inhibition

Emerging research indicates BPC-157 and its analogs may act as acetylcholinesterase inhibitors, potentially affecting cholinergic signaling pathways. However, the clinical significance of this mechanism is not yet established.

Tissue Repair and Pain Modulation

Preclinical evidence suggests BPC-157 may influence tissue regeneration and pain management pathways, with one clinical trial currently investigating its effects on muscle strain repair. The specific molecular mechanisms underlying these effects have not been fully characterized.

Evidence Limitations

The current understanding of BPC-157's mechanism of action is based primarily on preclinical studies in animal models. The molecular targets, receptor interactions, and precise signaling pathways remain incompletely defined. Clinical evidence is extremely limited, with only one small Phase 2 trial currently recruiting patients.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Consult with a healthcare provider before considering any investigational therapies.